齐拉西酮对wistar白化大鼠强迫游泳模型的抗抑郁作用

Hansraj Kumar, A. Das, S. Mondal, R. Kumar, U. P. Keshri, M. Gari
{"title":"齐拉西酮对wistar白化大鼠强迫游泳模型的抗抑郁作用","authors":"Hansraj Kumar, A. Das, S. Mondal, R. Kumar, U. P. Keshri, M. Gari","doi":"10.7439/IJPR.V6I10.3709","DOIUrl":null,"url":null,"abstract":"Background: Major depressive disorder is a common psychiatric condition and response conventional antidepressant drugs are sometimes unpredictable. Atypical antipsychotics by virtue of their pharmacodynamic profile show potential antidepressant effect.  Newer antidepressants as monotherapy or as augmenting agent for current therapy are need of the day. Ziprasidone is an atypical antidepressant drug possesses potential antidepressant activity by virtue of its 5HT1A agonistic activity and 5HT1D, 5HT2A and D2 receptors antagonistic activity. Method : Since its introduction in 1977 the forced swimming test model is still being used for evaluation of potential antidepressant molecule. 30 healthy male Wistar albino rat of 150-200 grams weight were divided in 3 groups with 10 rats in each. Group A was treated with 0.9% Normal Saline, Group B with Fluoxetine and Group C with Ziprasidone for 42 days. Forced Swimming test was done on day 0, 7, 14, 21, 28, 35 and 42 days. Result: After 42 days of treatment both fluoxetine and ziprasidone shows significant antidepressant activity. In comparison to Normal saline both the drugs shows significant antidepressant activity. There is significant deference in antidepressant activity between Fluoxetine and Ziprasidone. Antidepressant activity of Fluoxetine started to appear from day 7 with p vale of 0.000 and of Ziprasidone started to appear from 14 days with p value of 0.000.  Conclusion: Ziprasidone as virtue of its diverse pharmacodynamic effect can be suitable candidate for clinical trials of MDD as monotherapy or as an augmenting agent of standard antidepressant therapy.","PeriodicalId":14194,"journal":{"name":"International Journal of Pharmacological Research","volume":"15 1","pages":"316-321"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antidepressant effect of Ziprasidone in wistar albino rat by forced swimming test model\",\"authors\":\"Hansraj Kumar, A. Das, S. Mondal, R. Kumar, U. P. Keshri, M. Gari\",\"doi\":\"10.7439/IJPR.V6I10.3709\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Major depressive disorder is a common psychiatric condition and response conventional antidepressant drugs are sometimes unpredictable. Atypical antipsychotics by virtue of their pharmacodynamic profile show potential antidepressant effect.  Newer antidepressants as monotherapy or as augmenting agent for current therapy are need of the day. Ziprasidone is an atypical antidepressant drug possesses potential antidepressant activity by virtue of its 5HT1A agonistic activity and 5HT1D, 5HT2A and D2 receptors antagonistic activity. Method : Since its introduction in 1977 the forced swimming test model is still being used for evaluation of potential antidepressant molecule. 30 healthy male Wistar albino rat of 150-200 grams weight were divided in 3 groups with 10 rats in each. Group A was treated with 0.9% Normal Saline, Group B with Fluoxetine and Group C with Ziprasidone for 42 days. Forced Swimming test was done on day 0, 7, 14, 21, 28, 35 and 42 days. Result: After 42 days of treatment both fluoxetine and ziprasidone shows significant antidepressant activity. In comparison to Normal saline both the drugs shows significant antidepressant activity. There is significant deference in antidepressant activity between Fluoxetine and Ziprasidone. Antidepressant activity of Fluoxetine started to appear from day 7 with p vale of 0.000 and of Ziprasidone started to appear from 14 days with p value of 0.000.  Conclusion: Ziprasidone as virtue of its diverse pharmacodynamic effect can be suitable candidate for clinical trials of MDD as monotherapy or as an augmenting agent of standard antidepressant therapy.\",\"PeriodicalId\":14194,\"journal\":{\"name\":\"International Journal of Pharmacological Research\",\"volume\":\"15 1\",\"pages\":\"316-321\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmacological Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7439/IJPR.V6I10.3709\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmacological Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7439/IJPR.V6I10.3709","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:重度抑郁症是一种常见的精神疾病,常规抗抑郁药物的反应有时难以预测。非典型抗精神病药物凭借其药效学特征显示出潜在的抗抑郁作用。目前需要新的抗抑郁药作为单一疗法或作为当前治疗的增强剂。齐拉西酮是一种非典型抗抑郁药物,具有5HT1A的激动作用和5HT1D、5HT2A、D2受体的拮抗作用,具有潜在的抗抑郁活性。方法:强迫游泳试验模型自1977年推出以来,至今仍被用于评估潜在抗抑郁分子。选取体重150 ~ 200 g的健康雄性Wistar白化大鼠30只,随机分为3组,每组10只。A组用0.9%生理盐水治疗,B组用氟西汀治疗,C组用齐拉西酮治疗,疗程42 d。分别于第0、7、14、21、28、35、42天进行强迫游泳试验。结果:治疗42天后氟西汀和齐拉西酮均表现出明显的抗抑郁活性。与生理盐水相比,这两种药物都显示出显著的抗抑郁活性。氟西汀与齐拉西酮抗抑郁活性有显著差异。氟西汀从第7天开始出现抗抑郁活性,p值为0.000;齐拉西酮从第14天开始出现抗抑郁活性,p值为0.000。结论:齐拉西酮具有多种不同的药效学作用,可作为治疗重度抑郁症的单一药物或标准抗抑郁药物的辅助药物进行临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antidepressant effect of Ziprasidone in wistar albino rat by forced swimming test model
Background: Major depressive disorder is a common psychiatric condition and response conventional antidepressant drugs are sometimes unpredictable. Atypical antipsychotics by virtue of their pharmacodynamic profile show potential antidepressant effect.  Newer antidepressants as monotherapy or as augmenting agent for current therapy are need of the day. Ziprasidone is an atypical antidepressant drug possesses potential antidepressant activity by virtue of its 5HT1A agonistic activity and 5HT1D, 5HT2A and D2 receptors antagonistic activity. Method : Since its introduction in 1977 the forced swimming test model is still being used for evaluation of potential antidepressant molecule. 30 healthy male Wistar albino rat of 150-200 grams weight were divided in 3 groups with 10 rats in each. Group A was treated with 0.9% Normal Saline, Group B with Fluoxetine and Group C with Ziprasidone for 42 days. Forced Swimming test was done on day 0, 7, 14, 21, 28, 35 and 42 days. Result: After 42 days of treatment both fluoxetine and ziprasidone shows significant antidepressant activity. In comparison to Normal saline both the drugs shows significant antidepressant activity. There is significant deference in antidepressant activity between Fluoxetine and Ziprasidone. Antidepressant activity of Fluoxetine started to appear from day 7 with p vale of 0.000 and of Ziprasidone started to appear from 14 days with p value of 0.000.  Conclusion: Ziprasidone as virtue of its diverse pharmacodynamic effect can be suitable candidate for clinical trials of MDD as monotherapy or as an augmenting agent of standard antidepressant therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信